Stockscreener 앱 받기
65.27
0.14%
-0.095
전일 마감가:
$65.36
열려 있는:
$65.4
하루 거래량:
442.75K
Relative Volume:
0.26
시가총액:
$7.74B
수익:
$1.40B
순이익/손실:
$316.89M
주가수익비율:
26.19
EPS:
2.4918
순현금흐름:
$644.59M
1주 성능:
-6.18%
1개월 성능:
+5.90%
6개월 성능:
-0.88%
1년 성능:
+7.90%
1일 변동 폭
$65.25
$66.66
1주일 범위
$64.80
$70.32
52주 변동 폭
$47.50
$82.22
Halozyme Therapeutics Inc Stock (HALO) Company Profile
명칭
Halozyme Therapeutics Inc
전화
(858) 794-8889
주소
12390 EL CAMINO REAL, SAN DIEGO, CA
Compare HALO vs VRTX, REGN, ARGX, ALNY, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
HALO
Halozyme Therapeutics Inc
|
65.29 | 7.74B | 1.40B | 316.89M | 644.59M | 2.4918 |
VRTX
Vertex Pharmaceuticals Inc
|
427.99 | 109.45B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
745.97 | 79.46B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
788.33 | 48.52B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
306.05 | 40.77B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
298.36 | 33.39B | 5.36B | 287.73M | 924.18M | 2.5229 |
Halozyme Therapeutics Inc Stock (HALO) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-12-04 | 다운그레이드 | Goldman | Neutral → Sell |
| 2025-10-14 | 업그레이드 | Leerink Partners | Underperform → Market Perform |
| 2025-08-06 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2025-07-10 | 재개 | Goldman | Neutral |
| 2025-05-14 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2025-05-13 | 다운그레이드 | Leerink Partners | Market Perform → Underperform |
| 2024-10-07 | 다운그레이드 | Wells Fargo | Overweight → Equal Weight |
| 2024-09-19 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2024-06-07 | 다운그레이드 | Piper Sandler | Overweight → Neutral |
| 2024-02-29 | 개시 | TD Cowen | Outperform |
| 2023-07-24 | 다운그레이드 | Goldman | Buy → Neutral |
| 2023-07-24 | 개시 | H.C. Wainwright | Buy |
| 2023-05-10 | 업그레이드 | Piper Sandler | Neutral → Overweight |
| 2023-03-27 | 재개 | Berenberg | Buy |
| 2023-03-16 | 다운그레이드 | SVB Securities | Outperform → Market Perform |
| 2022-12-21 | 재개 | Morgan Stanley | Overweight |
| 2022-11-28 | 개시 | Wells Fargo | Overweight |
| 2022-09-09 | 개시 | Morgan Stanley | Overweight |
| 2022-05-23 | 개시 | SVB Leerink | Outperform |
| 2021-06-14 | 개시 | Evercore ISI | Outperform |
| 2021-05-17 | 개시 | SVB Leerink | Outperform |
| 2021-05-11 | 다운그레이드 | Piper Sandler | Overweight → Neutral |
| 2021-01-21 | 재확인 | The Benchmark Company | Buy |
| 2020-12-17 | 개시 | Berenberg | Buy |
| 2020-09-14 | 재개 | JP Morgan | Overweight |
| 2020-07-01 | 개시 | The Benchmark Company | Buy |
| 2020-02-05 | 업그레이드 | Piper Sandler | Neutral → Overweight |
| 2020-01-09 | 업그레이드 | BMO Capital Markets | Market Perform → Outperform |
| 2020-01-08 | 개시 | Goldman | Buy |
| 2019-11-05 | 업그레이드 | Barclays | Underweight → Equal Weight |
| 2018-10-19 | 재개 | Piper Jaffray | Neutral |
| 2018-05-11 | 다운그레이드 | Barclays | Equal Weight → Underweight |
| 2018-01-24 | 개시 | Goldman | Neutral |
| 2017-10-16 | 재확인 | Piper Jaffray | Overweight |
| 2017-01-06 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2016-11-03 | 개시 | Deutsche Bank | Buy |
| 2015-12-04 | 개시 | Wells Fargo | Outperform |
| 2015-11-18 | 개시 | Citigroup | Buy |
| 2015-09-22 | 개시 | Barclays | Overweight |
| 2015-06-22 | 재확인 | JP Morgan | Overweight |
| 2015-03-03 | 재확인 | UBS | Buy |
| 2015-02-18 | 재확인 | MLV & Co | Buy |
| 2015-01-08 | 재확인 | MLV & Co | Buy |
모두보기
Halozyme Therapeutics Inc 주식(HALO)의 최신 뉴스
Why is Halozyme Therapeutics (HALO) down 13.1% since last earnings report? - MSN
Halozyme raises outlook, buys Surf Bio - MSN
Halozyme granted injunction in Germany barring Merck's subcutaneous Keytruda - MSN
Vertex Pharma in pact with Halozyme for Hypercon drug delivery tech - MSN
Halozyme Therapeutics Inc (HAM:RV7) Stock Price & 30 Year Financial Data - GuruFocus
Why Is Halozyme Therapeutics (HALO) Down 2.2% Since Last Earnings Report? - MSN
Halozyme Therapeutics prices $1.3 billion convertible notes - MSN
Halozyme Therapeutics Inc. (HALO) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Halozyme Therapeutics updates bylaws on director removal and stockholder meetings By Investing.com - Investing.com South Africa
Halozyme Therapeutics updates bylaws on director removal and stockholder meetings - Investing.com
Halozyme (NASDAQ: HALO) board revises bylaws on director removal, meetings - Stock Titan
Asset Management One Co. Ltd. Increases Stock Position in Halozyme Therapeutics, Inc. $HALO - MarketBeat
HALO Price Today: Halozyme Therapeutics, Inc. Stock Price, Quote & Chart | MEXC - MEXC Exchange
Is It Too Late To Consider Halozyme Therapeutics (HALO) After Its Recent Share Price Rebound - Sahm
HALO (Halozyme Therapeutics) rises 0.95 percent as Q4 2025 37.5 percent revenue growth offsets steep EPS miss. - Xã Thanh Hà
HALO Stock Price, Quote & Chart | HALOZYME THERAPEUTICS INC (NASDAQ:HALO) - ChartMill
HALO (Halozyme Therapeutics) edges up 0.4 percent after Q4 2025 results, with 37.5 percent revenue growth offsetting steep EPS miss.Gamma Squeeze - Cổng thông tin điện tử tỉnh Lào Cai
Halozyme Therapeutics (HALO) Stock: Risk Factors (Investor Interest) 2026-04-22Expert Verified Trades - Cổng thông tin điện tử Tỉnh Sơn La
Boston Trust Walden Corp Sells 52,058 Shares of Halozyme Therapeutics, Inc. $HALO - MarketBeat
Choreo LLC Sells 28,448 Shares of Halozyme Therapeutics, Inc. $HALO - MarketBeat
Is Halozyme Therapeutics (HALO) Offering Value After Mixed Multi Year Share Price Performance - Yahoo Finance
Goldman Sachs Maintains Halozyme Therapeutics (HALO) Neutral Recommendation - MSN
Halozyme Therapeutics, Inc. Experiences Revision in Its Stock Evaluation Amid Mixed Performance Metrics - Markets Mojo
Morgan Stanley Maintains Halozyme Therapeutics(HALO.US) With Buy Rating, Raises Target Price to $96 - Moomoo
(HALO) Movement as an Input in Quant Signal Sets - Stock Traders Daily
Halozyme Therapeutics Partners with Vertex for Hypercon Technology - HarianBasis.co
Is Halozyme Therapeutics (HALO) stock reacting to risk factors (+0.06%) 2026-04-20Certified Trade Ideas - Cổng thông tin điện tử Tỉnh Sơn La
Halozyme Therapeutics, Inc. (HALO) Stock Analysis: Unpacking the 22.67% Potential Upside - DirectorsTalk Interviews
Assessing Halozyme Therapeutics (HALO) Valuation After Recent Share Price Strength Without Major News - Sahm
Is Halozyme Therapeutics (HALO) One of the Most Undervalued Biotech Stocks to Buy Right Now? - Insider Monkey
Lobbying Update: $70,000 of HALOZYME THERAPEUTICS INC. lobbying was just disclosed - Quiver Quantitative
Halozyme Therapeutics Inc at Leerink Global Healthcare Conference Transcript - GuruFocus
8 Most Undervalued Biotech Stocks to Buy Right Now - Insider Monkey
Assetmark Inc. Has $9.25 Million Position in Halozyme Therapeutics, Inc. $HALO - MarketBeat
Halozyme Therapeutics (HALO) to Report Q4 Results: Wall Street Expects Earnings Growth - Eastern Progress
Halozyme Therapeutics, Inc. Experiences Revision in Stock Evaluation Amid Market Dynamics - Markets Mojo
CapEx per share of Halozyme Therapeutics, Inc. – BX:RV7 - TradingView — Track All Markets
Working capital per share of Halozyme Therapeutics, Inc. – BX:RV7 - TradingView — Track All Markets
Halozyme Therapeutics (HALO) appoints interim CFO amid growth plans - MSN
TD Cowen reiterates Halozyme stock Buy rating on royalty growth By Investing.com - Investing.com Canada
Paragon Capital Boosts Stake in Halozyme Therapeutics - National Today
Paragon Capital Management Inc. Purchases New Shares in Halozyme Therapeutics, Inc. $HALO - MarketBeat
A Look At Halozyme Therapeutics (HALO) Valuation After New Vertex Collaboration And Licensing Deal - Sahm
Halozyme Therapeutics Inc (HAM:RV7) Dividend - GuruFocus
Halozyme Therapeutics, Inc. (HALO) Stock Analysis: A Biotech Powerhouse with 25% Upside Potential - DirectorsTalk Interviews
Halozyme Vertex Hypercon Deal Opens New Royalty And Growth Pathways - Sahm
HALO (Halozyme Therapeutics) Dividends Paid - GuruFocus
HALO (Halozyme Therapeutics) Unearned Premiums - GuruFocus
Did Halozyme’s Vertex Hypercon Licensing Deal Just Shift Halozyme Therapeutics’ (HALO) Investment Narrative? - Yahoo Finance
Liquidity Mapping Around (HALO) Price Events - Stock Traders Daily
Halozyme (HALO) loses 9% on weak earnings - MSN
Halozyme Therapeutics Inc (HALO) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Halozyme Therapeutics Inc 주식 (HALO) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Torley Helen | PRESIDENT AND CEO |
Apr 06 '26 |
Sale |
63.50 |
10,000 |
634,982 |
767,780 |
| Torley Helen | PRESIDENT AND CEO |
Apr 01 '26 |
Option Exercise |
12.07 |
20,000 |
241,400 |
787,780 |
| Torley Helen | PRESIDENT AND CEO |
Apr 02 '26 |
Option Exercise |
12.07 |
20,000 |
241,400 |
787,780 |
| Torley Helen | PRESIDENT AND CEO |
Apr 01 '26 |
Sale |
65.38 |
20,000 |
1,307,516 |
767,780 |
| Torley Helen | PRESIDENT AND CEO |
Apr 02 '26 |
Sale |
64.24 |
20,000 |
1,284,721 |
767,780 |
| Caudill Cortney | SVP, CHIEF OPERATING OFFICER |
Mar 09 '26 |
Option Exercise |
33.51 |
20,000 |
670,200 |
34,366 |
| Caudill Cortney | SVP, CHIEF OPERATING OFFICER |
Mar 10 '26 |
Option Exercise |
33.51 |
1,546 |
51,806 |
15,912 |
| Caudill Cortney | SVP, CHIEF OPERATING OFFICER |
Mar 09 '26 |
Sale |
67.80 |
20,000 |
1,356,072 |
14,366 |
| Caudill Cortney | SVP, CHIEF OPERATING OFFICER |
Mar 10 '26 |
Sale |
67.64 |
8,857 |
599,087 |
7,055 |
1.73%
2.52%
자본화:
|
볼륨(24시간):